WE ARE A SPECIALISED ONCOLOGY AND ONCO-HAEMATOLOGY LEADER WITH OPERATIONAL EXCELLENCE IN THE DEVELOPMENT OF CANCER TREATMENTS.

At Pivotal Oncology/Haematology is one of our leading therapeutic areas, our knowledge will expedite every aspect of the drug development programme and will efficiently guide our clients to address the unique challenges of cancer research. Our clients will have access to our internal network of Oncology/Haematology professionals and sites which can significantly impact the study success. We have the right capabilities to accelerate study start-up, help design and plan the development strategy and execute the study on time and on budget.

In the past years, Pivotal has conducted 174 trials assessing over 16,481 patients at nearly 2,674 sites across 76 types of cancer drugs.

More than fifty percent of our staff has experience in oncology and haematology studies with services spanning from Phase I to commercialisation. In particular, Pivotal brings both therapeutic and operational expertise to early phase oncology trials across Europe with over 60% of the total trials performed.